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Abstract 
Purpose: To report on 2 cases of aggressive posterior retinopathy of prematurity (ROP) 
treated with intravitreal ranibizumab (Lucentis®) and laser photocoagulation.  
Methods: Two premature females, born at 25 and 26 weeks’ gestation with a birth weight of 
530 and 550 g, respectively, with aggressive posterior ROP received combined treatment 
with laser photocoagulation and intravitreal ranibizumab (0.3 mg [30 µl]) to each eye. 
Structural outcomes were evaluated by indirect ophthalmoscopy and documented by 
retinography.  
Results: An intravitreal injection was made at 34 weeks of postmenstrual age in the first 
case, followed by laser photocoagulation 1 week later. There was a partial regression of ROP 
with treatment. Five weeks later, neovascularization regrowth with bleeding in both eyes 
(intraretinal and subhyaloid) occurred and retreatment with combined therapy was 
performed. In the second case, single therapy with laser photocoagulation was made at 34 
weeks of postmenstrual age. In spite of the confluent photocoagulation in the avascular 
area, progression to 4A ROP stage occurred 1 week later. Both eyes were retreated 1 week 
later with intravitreal ranibizumab and laser photocoagulation. Treatment resulted in ROP 
regression in both cases. There were no signs of systemic or ocular adverse side effects.  
Conclusion: The cases presented show that combination therapy of indirect laser 
photocoagulation and intravitreal ranibizumab can be effective in the management of  
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aggressive posterior ROP. Further investigation on anti-VEGF safety in premature infants is 
necessary . Additional studies are needed to define the role of anti-VEGF in ROP treatment. 
 
Introduction 
Retinopathy of prematurity (ROP) is a proliferative disease that affects infants of low 
birth weight and young gestational age [1]. Both CRYO-ROP [2] and Early Treatment 
ROP [3] demonstrated improvements in the structural and functional outcomes with 
peripheral ablation therapy. 
The role of VEGF in the pathogenesis of ROP has been described [4]. Many recent 
reports of anti-VEGF use in ROP showed that it can be a safe and effective treatment [4–
8]. However, there is concern about the choice of the drug, dose and time of injection as 
well as about local and systemic potential complications [4]. 
Aggressive posterior ROP (APROP) is a rapidly progressing and severe form of ROP 
that, if untreated, progresses to stage 5. Eyes with APROP have a worse prognosis and a 
higher rate of retinal detachment [1]. 
The present report describes 2 cases of APROP treated with combined therapy 
including intravitreal ranibizumab (Lucentis®) and laser photocoagulation. 
Methods 
ROP classification was defined according to The International Classification of Retinopathy of 
Prematurity Revisited [9]. APROP was characterized as stage 3 zone I with plus or preplus disease. 
The off-label use of anti-VEGF and the potential risks were discussed with the parents and written 
informed consent was obtained. All procedures were made under general anesthesia. Disinfection 
with povidone-iodine was made before the injections. Sterile gloves, speculum and forceps were used 
to perform the injections. Sterile unit doses of ranibizumab (0.3 mg [30 µl]) were injected using a  
30-gauge needle, placed 2.5 mm posterior to the limbus. Immediately after the injection, and every  
3 h for the next 7 days, topical ofloxacin was administered. Indirect ophthalmoscopy was used to look 
for any injury after the injections. Laser photocoagulation was applied to the 360° avascular retina, 
extending to the ora serrata with confluent impacts. The systemic condition was closely monitored in 
the neonatal intensive care unit. Both cases were photographed using RetCam 3 (Clarity Medical 
Systems, Pleasanton, Calif., USA). Follow-up was made weekly during the first month and then 
monthly until total regression of ROP. 
Results 
The first case was a female premature infant born at 25 weeks of gestation with a 
birth weight of 530 g. Her first screening examination was at 33 weeks of 
postmenstrual age, showing bilateral stage 3 zone I ROP with plus disease, intraretinal 
hemorrhages and extensive subhyaloid hemorrhage in the left eye (fig. 1). There was 
also bilateral tunica vasculosa lentis and pupillary rigidity. Ranibizumab was injected in 
both eyes 72 h after observation. One week after the treatment, there was complete 
regression of anterior segment vessels, reduction in central vascular dilation and 
tortuosity and decrease of hemorrhagic collections. Laser photocoagulation was made 1  
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week after the injection. Four weeks later, there was a new subhyaloid hemorrhage in 
the left eye and maintenance of some intraretinal hemorrhages in the right eye. It was 
decided to make a second injection of ranibizumab and to increase laser photoablation 
in both eyes (fig. 2). Total regression of neovascularization was observed 1 week later 
in the right and 4 weeks later in the left eye. 
The second case was a female premature infant born at 26 weeks of gestation with a 
birth weight of 550 g. Her first screening examination was at 33 weeks of 
postmenstrual age, showing bilateral stage 3 zone I ROP with plus disease and 
intraretinal hemorrhages. Laser photocoagulation was made 72 h after observation. 
One week after the treatment, there was progression of the disease to stage 4A and 
extrafoveal partial retinal detachment occurred (fig. 3). Ranibizumab injection and 
densification of laser photocoagulation in the avascular area were made bilaterally. 
Two weeks after combined treatment, regression of neovascularization could be 
observed (fig. 4). 
Discussion 
There are multiple reports using anti-VEGF for ROP treatment. Micieli et al. [6] 
showed some variability in the off-label use of bevacizumab, mainly regarding dose, 
time of injection and frequency of administration. ROP is less likely than choroidal 
neovascularization or diabetic retinopathy to necessitate repeated injections since the 
disease is known to undergo spontaneous involution in 90% of patients after 44 weeks 
of postmenstrual age [10]. The vascularization of the preterm peripheral retina is a 
finite process. Once the peripheral inner retinal vessels develop, the disease process 
does not recur [4]. Potential benefits of using anti-VEGF treatment include eliminating 
visual field loss due to retinal laser ablation. Injections may be administered in very 
sick infants to avoid general anesthesia risks, and they are easy to perform even in 
infants with opaque media because of anterior segment involvement [4]. Complications 
can occur with intravitreal injections. Jang et al. [11] reported on a patient with 
bilateral zone I stage 3 plus ROP who was treated with combined laser 
photocoagulation and ranibizumab and showed full regression 3 months after 
treatment but then developed bilateral retinal detachment. Honda et al. [12] reported 
on a patient with acute contraction of the proliferative membrane that resulted in 
funnel-like retinal detachment after intravitreal bevacizumab for stage 4A ROP. In 
recent reports, anti-VEGF was used as first-line therapy with complete regression of 
neovascularization without the need for further treatment [5]. Mintz-Hittner and Kuffel 
[4] reported that intravitreal injection is a safe and effective treatment for stage 3 ROP 
in zone I and II. No systemic complications have been reported to date. Some authors 
consider that long-term systemic complications are unlikely following a single injection 
of a small quantity of anti-VEGF into the vitreous cavity [7]. We used ranibizumab 
because it has a shorter systemic half-life than bevacizumab [13–15], which in our 
opinion may reduce the risk of systemic complications in premature infants. On the 
other hand, the shorter half-life in vitreous humor may explain the need for 
reintervention in the first case. Several investigators have confirmed the presence of 
bevacizumab in the serum after an intravitreal injection, which lasted for 1–2 weeks. 
Also, there are reports of dramatic reductions in the systemic VEGF levels following 
intravitreal bevacizumab, which seems to continue for several days [15].  
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This is the second report using ranibizumab as ROP treatment. There were no signs 
of systemic or ocular adverse side effects until the time of this report. The combination 
therapy was effective in the management of APROP. Further investigation on anti-VEGF 
safety in ROP treatment is necessary. 
 
 
 
 
 
 
Fig. 1. Bilateral stage 3 zone I ROP with plus disease, intraretinal hemorrhages and extensive 
subhyaloid hemorrhage in the left eye. 
 
 
 
Fig. 2.  Total regression of neovascularization could be observed in both eyes after the treatment. 
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Fig. 3. One week after laser treatment, progression of the disease to stage 4A could be observed in the 
left eye. 
 
 
 
Fig. 4. Two weeks after combined treatment, regression of neovascularization could be observed. 
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